What is Adela?
Adela is at the forefront of developing a routine blood test capable of detecting cancer and other high-morbidity, high-mortality conditions. The company's proprietary genome-wide methylation analysis technology is distinguished by its ability to precisely identify and target the most informative methylated regions of the genome for sequencing. This innovative approach is initially being optimized for the comprehensive management of cancer, spanning detection, diagnosis, and ongoing treatment monitoring. Looking ahead, Adela plans to extend its diagnostic capabilities to a broader spectrum of serious health conditions beyond oncology, aiming to provide earlier and more accurate insights into patient health.
How much funding has Adela raised?
Adela has raised a total of $53M across 2 funding rounds:
Other Financing Round
$48M
Debt
$5M
Other Financing Round (2023): $48M with participation from OrbiMed, RA Capital Management, Deerfield, F-Prime Capital Partners, and Decheng Capital
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Adela
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. Their investment approach combines deep life sciences expertise with a comprehensive understanding of healthcare market dynamics, supporting companies from early-stage ventures to scaling organizations.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies. They partner with innovators to advance therapies and diagnostics, with a growing interest in climate and sustainability technologies.
Deerfield
Deerfield Management is an investment firm committed to advancing healthcare through investment, intelligence, and philanthropy. They support companies across the healthcare ecosystem with flexible funding and leverage AI and data to drive innovation, also engaging in philanthropic initiatives.
What's next for Adela?
The substantial enterprise-level backing Adela has garnered, including its recent strategic investment, positions the company for significant scaling and market penetration. This financing is anticipated to fuel further research and development, enhance clinical validation efforts, and support the expansion of its commercialization strategy. Adela's focus on a routine blood test for complex diseases signifies a shift towards more accessible and proactive healthcare, with the company poised to become a leader in the next generation of diagnostic solutions. The strategic nature of the recent capital suggests strong confidence from investors in Adela's technology and its potential to disrupt the diagnostic landscape.
See full Adela company page
